Bristol Myers (BMY) Squibb announced that the European Commission has granted approval to Breyanzi, a CD19-directed chimeric antigen receptor T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bayer data could ‘somewhat renew’ optimism for Bristol drug, says Morgan Stanley
- Video: Biogen up after Novo weight-loss drug fails to slow Alzheimer’s progress
- Texas AG sues Sanofi, Bristol Myers over alleged Plavix inefficacy
- Bristol-Myers Squibb: Balancing Phase III Setbacks with Future Opportunities in Stroke and Atrial Fibrillation
- Bristol-Myers Squibb Adjusts Tender Offer Terms